Prostate Cancer
Disparities and Trends in Genitourinary Cancer Incidence and Mortality in the USA.
December 28, 2022
Combining PSA and PET features to select candidates for salvage lymph node dissection in recurrent prostate cancer.
December 28, 2022
Association of rare, recurrent nonsynonymous variants in the germline of prostate cancer patients of African ancestry.
December 28, 2022
Performance of multiparametric prostate magnetic resonance imaging validated by targeted and systematic transperineal biopsies.
December 28, 2022
Cyclotron vs generator-produced 68Ga PSMA: a single-institution, prospective clinical trial.
December 28, 2022
Long Term Results of a Phase III Randomized Prospective Trial of Erectile Tissue Sparing IMRT for Men with Clinically Localized Prostate Cancer.
December 27, 2022
IL-1β expression driven by androgen receptor absence or inactivation promotes prostate cancer bone metastasis.
December 27, 2022
Prostate specific membrane antigen binding radiopharmaceuticals: Current data and new concepts.
December 26, 2022
Outcomes of Grade Group 2 and 3 Prostate Cancer on Initial Versus Confirmatory Biopsy: Implications for Active Surveillance.
December 26, 2022
Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer.
December 26, 2022
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide.
December 26, 2022
Network analysis of depression in prostate cancer patients: Implications for assessment and treatment.
December 23, 2022
Changes in neutrophile-to-lymphocyte ratio as predictive and prognostic biomarker in metastatic prostate cancer treated with taxane-based chemotherapy.
December 23, 2022
Is 18F-FDG PET needed to assess 177Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis.
December 23, 2022
Should Transperineal Prostate Biopsy Be the Standard of Care?
December 23, 2022